Soligenix names Marco Brughera to board
This article was originally published in Scrip
Princeton, New Jersey-based Soligenix – a clinical stage biopharmaceutical company developing products to treat inflammatory diseases and biodefense medical countermeasures – has named Marco Maria Brughera to its board of directors. Dr Brughera is currently global head of the rare disease franchise for Sigma-tau, he is also a member of the company's board. Furthermore Dr Brughera is currently a member of the board for Italian biopharmaceutical company Gentium.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.